Literature DB >> 31220271

Allele length of the DMPK CTG repeat is a predictor of progressive myotonic dystrophy type 1 phenotypes.

Gayle Overend1, Cécilia Légaré2,3,4, Jean Mathieu5,4, Luigi Bouchard2,3,4, Cynthia Gagnon5,4, Darren G Monckton1.   

Abstract

Myotonic dystrophy type 1 (DM1) is an autosomal dominant inherited disorder caused by expansion of a germline and somatically unstable CTG repeat in the DMPK gene. Previously, CTG repeat length at birth has been correlated to patient age at symptom onset. Attempts to correlate CTG repeat length with progressive DM1 phenotypes, such as muscle power, have proven difficult. To better correlate genotype with progressive phenotypes, we have measured CTG repeat tract length and screened for interrupting variant repeats in 192 study participants from a well-characterized Canadian cohort. We have assessed genotype-phenotype correlations with nine progressive measures of skeletal muscle power and respiratory function. We have built statistical models that include confounding factors such as sex, age, height and weight to further explain variation in muscle power. Our analysis reveals a strong correlation between DM1 genotype and respiratory function and skeletal muscle power, as part of a complex model that includes additional modulators such as sex, age, height, weight and the presence or absence of interrupting variant repeats. Distal skeletal muscle measurements, such as hand pinch and grip strength, show the strongest correlation with disease genotype. Detailed analysis of CTG repeat length, and incorporation of confounding factors, greatly improves the predictive ability of these models. They reveal a greater genetic influence on individual progressive phenotypes than on age at symptom onset and for clinical trials will help optimize stratification and explain patient variability. They will also help practitioners prioritize assessment of the muscular power measurements that correlate best with disease severity.
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31220271      PMCID: PMC6586140          DOI: 10.1093/hmg/ddz055

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  40 in total

1.  Epidemiological surveillance of myotonic dystrophy type 1: a 25-year population-based study.

Authors:  Jean Mathieu; Claude Prévost
Journal:  Neuromuscul Disord       Date:  2012-08-01       Impact factor: 4.296

Review 2.  Myotonic dystrophy: disease repeat range, penetrance, age of onset, and relationship between repeat size and phenotypes.

Authors:  Kevin Yum; Eric T Wang; Auinash Kalsotra
Journal:  Curr Opin Genet Dev       Date:  2017-02-14       Impact factor: 5.578

3.  Identification and characterization of 5' CCG interruptions in complex DMPK expanded alleles.

Authors:  Annalisa Botta; Giulia Rossi; Marzia Marcaurelio; Luana Fontana; Maria Rosaria D'Apice; Francesco Brancati; Roberto Massa; Darren G Monckton; Federica Sangiuolo; Giuseppe Novelli
Journal:  Eur J Hum Genet       Date:  2016-11-23       Impact factor: 4.246

4.  Somatic instability of CTG repeats in the cerebellum of myotonic dystrophy type 1.

Authors:  Kenji Jinnai; Maki Mitani; Naonobu Futamura; Kunihiko Kawamoto; Itaru Funakawa; Kyoko Itoh
Journal:  Muscle Nerve       Date:  2013-04-29       Impact factor: 3.217

5.  Variant CCG and GGC repeats within the CTG expansion dramatically modify mutational dynamics and likely contribute toward unusual symptoms in some myotonic dystrophy type 1 patients.

Authors:  Claudia Braida; Rhoda K A Stefanatos; Berit Adam; Navdeep Mahajan; Hubert J M Smeets; Florence Niel; Cyril Goizet; Benoit Arveiler; Michel Koenig; Clotilde Lagier-Tourenne; Jean-Louis Mandel; Catharina G Faber; Christine E M de Die-Smulders; Frank Spaans; Darren G Monckton
Journal:  Hum Mol Genet       Date:  2010-01-15       Impact factor: 6.150

6.  Leukocyte CTG repeat length correlates with severity of myotonia in myotonic dystrophy type 1.

Authors:  E L Logigian; R T Moxley; C L Blood; C A Barbieri; W B Martens; A W Wiegner; C A Thornton; R T Moxley
Journal:  Neurology       Date:  2004-04-13       Impact factor: 9.910

7.  Anticipation in myotonic dystrophy. I. Statistical verification based on clinical and haplotype findings.

Authors:  T Ashizawa; C J Dunne; J R Dubel; M B Perryman; H F Epstein; E Boerwinkle; J F Hejtmancik
Journal:  Neurology       Date:  1992-10       Impact factor: 9.910

8.  Gonosomal mosaicism in myotonic dystrophy patients: involvement of mitotic events in (CTG)n repeat variation and selection against extreme expansion in sperm.

Authors:  G Jansen; P Willems; M Coerwinkel; W Nillesen; H Smeets; L Vits; C Höweler; H Brunner; B Wieringa
Journal:  Am J Hum Genet       Date:  1994-04       Impact factor: 11.025

9.  Molecular, clinical, and muscle studies in myotonic dystrophy type 1 (DM1) associated with novel variant CCG expansions.

Authors:  Massimo Santoro; Marcella Masciullo; Roberta Pietrobono; Giulia Conte; Anna Modoni; Maria Laura E Bianchi; Valentina Rizzo; Maria Grazia Pomponi; Giorgio Tasca; Giovanni Neri; Gabriella Silvestri
Journal:  J Neurol       Date:  2012-12-23       Impact factor: 4.849

10.  Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member.

Authors:  J D Brook; M E McCurrach; H G Harley; A J Buckler; D Church; H Aburatani; K Hunter; V P Stanton; J P Thirion; T Hudson
Journal:  Cell       Date:  1992-02-21       Impact factor: 41.582

View more
  13 in total

Review 1.  DM1 Phenotype Variability and Triplet Repeat Instability: Challenges in the Development of New Therapies.

Authors:  Stéphanie Tomé; Geneviève Gourdon
Journal:  Int J Mol Sci       Date:  2020-01-10       Impact factor: 5.923

2.  Antisense oligonucleotide and adjuvant exercise therapy reverse fatigue in old mice with myotonic dystrophy.

Authors:  Ningyan Hu; Eunjoo Kim; Layal Antoury; Jia Li; Paloma González-Pérez; Seward B Rutkove; Thurman M Wheeler
Journal:  Mol Ther Nucleic Acids       Date:  2020-11-26       Impact factor: 8.886

3.  Associations Between Variant Repeat Interruptions and Clinical Outcomes in Myotonic Dystrophy Type 1.

Authors:  Stephan Wenninger; Sarah A Cumming; Kristina Gutschmidt; Kees Okkersen; Aura Cecilia Jimenez-Moreno; Ferroudja Daidj; Hanns Lochmüller; Fiona Hogarth; Hans Knoop; Guillaume Bassez; Darren G Monckton; Baziel G M van Engelen; Benedikt Schoser
Journal:  Neurol Genet       Date:  2021-03-09

4.  White matter microstructure relates to motor outcomes in myotonic dystrophy type 1 independently of disease duration and genetic burden.

Authors:  Timothy R Koscik; Ellen van der Plas; Laurie Gutmann; Sarah A Cumming; Darren G Monckton; Vincent Magnotta; Richard K Shields; Peggy C Nopoulos
Journal:  Sci Rep       Date:  2021-03-01       Impact factor: 4.379

Review 5.  The Contribution of Somatic Expansion of the CAG Repeat to Symptomatic Development in Huntington's Disease: A Historical Perspective.

Authors:  Darren G Monckton
Journal:  J Huntingtons Dis       Date:  2021

Review 6.  Molecular and Clinical Implications of Variant Repeats in Myotonic Dystrophy Type 1.

Authors:  Stojan Peric; Jovan Pesovic; Dusanka Savic-Pavicevic; Vidosava Rakocevic Stojanovic; Giovanni Meola
Journal:  Int J Mol Sci       Date:  2021-12-29       Impact factor: 5.923

Review 7.  Epigenetics of Myotonic Dystrophies: A Minireview.

Authors:  Virginia Veronica Visconti; Federica Centofanti; Simona Fittipaldi; Elisa Macrì; Giuseppe Novelli; Annalisa Botta
Journal:  Int J Mol Sci       Date:  2021-11-22       Impact factor: 5.923

8.  Variant repeats within the DMPK CTG expansion protect function in myotonic dystrophy type 1.

Authors:  Jacob N Miller; Ellen van der Plas; Mark Hamilton; Timothy R Koscik; Laurie Gutmann; Sarah A Cumming; Darren G Monckton; Peggy C Nopoulos
Journal:  Neurol Genet       Date:  2020-08-12

9.  Towards development of a statistical framework to evaluate myotonic dystrophy type 1 mRNA biomarkers in the context of a clinical trial.

Authors:  Adam Kurkiewicz; Anneli Cooper; Emily McIlwaine; Sarah A Cumming; Berit Adam; Ralf Krahe; Jack Puymirat; Benedikt Schoser; Lubov Timchenko; Tetsuo Ashizawa; Charles A Thornton; Simon Rogers; John D McClure; Darren G Monckton
Journal:  PLoS One       Date:  2020-04-14       Impact factor: 3.240

10.  Robust Detection of Somatic Mosaicism and Repeat Interruptions by Long-Read Targeted Sequencing in Myotonic Dystrophy Type 1.

Authors:  Antoine Mangin; Laure de Pontual; Yu-Chih Tsai; Laetitia Monteil; Mathilde Nizon; Pierre Boisseau; Sandra Mercier; Janet Ziegle; John Harting; Cheryl Heiner; Geneviève Gourdon; Stéphanie Tomé
Journal:  Int J Mol Sci       Date:  2021-03-05       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.